Your session is about to expire
← Back to Search
Stem Cell Therapy
Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose for Diabetic Kidney Disease
Phase 1
Waitlist Available
Led By LaTonya J Hickson, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through month 15
Awards & highlights
Study Summary
This trial will test if intra-arterially delivered autologous adipose tissue-derived mesenchymal stem/stromal cells are safe and effective in treating patients with progressive diabetic kidney disease.
Eligible Conditions
- Diabetic Kidney Disease
- Type 1 Diabetes
- Type 2 Diabetes
- Chronic Kidney Disease
- Kidney Failure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through month 15
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through month 15
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adverse Events
Secondary outcome measures
Kidney Function
Trial Design
2Treatment groups
Experimental Treatment
Group I: Lower Dose MSCExperimental Treatment1 Intervention
This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.
Group II: Higher Dose MSCExperimental Treatment1 Intervention
This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose
Find a Location
Who is running the clinical trial?
Regenerative Medicine MinnesotaUNKNOWN
Mayo ClinicLead Sponsor
3,245 Previous Clinical Trials
3,783,450 Total Patients Enrolled
LaTonya J Hickson, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
60 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger